Entera Bio (NASDAQ:ENTX) Shares Up 6%

Entera Bio Ltd. (NASDAQ:ENTXGet Free Report) was up 6% during mid-day trading on Monday . The company traded as high as $1.77 and last traded at $1.77. Approximately 47,530 shares traded hands during trading, a decline of 72% from the average daily volume of 172,747 shares. The stock had previously closed at $1.67.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Entera Bio in a research note on Wednesday, June 5th.

Read Our Latest Analysis on Entera Bio

Entera Bio Stock Performance

The business has a 50 day moving average of $2.14 and a 200-day moving average of $1.61. The firm has a market capitalization of $64.40 million, a P/E ratio of -6.43 and a beta of 1.60.

Entera Bio (NASDAQ:ENTXGet Free Report) last posted its earnings results on Friday, May 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts anticipate that Entera Bio Ltd. will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC acquired a new stake in Entera Bio Ltd. (NASDAQ:ENTXFree Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Company Profile

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

Further Reading

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.